Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1b Study of ARQ 092 in Combination With Other Antineoplastic Agents in Subjects With Selected Solid Tumors

NCT02476955 is registered in ClinicalTrials.gov with ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) as lead sponsor.

NCT NCT02476955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02476955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1b Study of ARQ 092 in Combination With Other Antineoplastic Agents in Subjects With Selected Solid Tumors
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase
Phase 1
Overall status
Terminated
Start date
June 9, 2015
Completion date
May 7, 2019
Enrollment
41 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, ovarian cancer, solid tumors